AKT1 and melanoma: The AKT-specific inhibitor MK-2206 has progressed to phase II clinical trials for advanced breast cancer [16] and phase I trials for multiple solid tumors, including melanoma, demonstrating favorable tolerability but variable therapeutic efficacy [25].